Almstead Neil Gregory 4

What Happened
Neil Gregory Almstead, Chief Technical Operations Officer at PTC Therapeutics (PTCT), exercised a total of 46,774 option shares and sold 46,774 common shares in transactions reported July 6–7, 2026. He exercised 19,687 shares at $38.10 and 27,087 shares at $39.42 (total exercise cost ≈ $1.82M) and sold the resulting shares in multiple open-market trades for total proceeds of ≈ $4.09M (net proceeds before taxes/fees ≈ $2.28M). The exercises and sales were effectively same-day (cashless-style disposition).

Key Details

• Transaction dates: July 6–7, 2026; Form 4 filed July 8, 2026 (appears timely).
• Options exercised: 46,774 shares (19,687 @ $38.10; 27,087 @ $39.42); total exercise cost ≈ $1,817,844.
• Shares sold: 46,774 shares in multiple trades for total proceeds ≈ $4,093,482 (weighted avg ≈ $87.5/share). Trade prices ranged roughly $85.00–$89.75 per footnotes.
• Net cash (proceeds minus exercise cost): roughly $2.28M before taxes and fees.
• Post-transaction holdings: not provided in the summary here — see the full Form 4 for shares owned after these transactions.
• Notable footnotes: some sales were executed pursuant to a written Rule 10b5-1 trading plan (adopted Nov 11, 2025); option grants and vesting tied to a Jan 5, 2023 grant schedule; several sale prices are reported as weighted averages across multiple trade prices. One footnote also notes 162 shares acquired under the issuer’s ESPP for the period ended June 30, 2026.

Context

• These were option exercises followed immediately by open-market sales of the same number of shares — a common cashless exercise/tax-covering pattern rather than an additional market purchase.
• Sales by officers are routine liquidity events and do not, by themselves, prove a change in insider sentiment. Purchases generally carry more direct informational weight than routine option exercises and subsequent sales.
• For full details (exact per-trade prices, post-transaction holdings, and which trades were under the 10b5-1 plan), consult the complete Form 4 filing (Accession No. 0001578850-26-000021).